Pf.Judson, Presentation on the CTOS 2008 annual meeting

[Olga]

CTOS 14th Annual Meeting
November 13–15, 2008
London United Kingdom
Saturday, November 15, 2008
Medical Oncology
Session Chairs: Shreyas Patel, Jeremy Whelan

#34936 ACTIVITY OF THE VEGFR/KIT TYROSINE KINASE INHIBITOR CEDIRANIB (AZD2171) IN ALVEOLAR SOFT PART SARCOMA.
Katherine Gardner; Michael Leahy; Manuel Alvarez-Gutierrez; Ian Judson; Michelle Scurr

ACTIVITY OF THE VEGFR/KIT TYROSINE KINASE INHIBITOR CEDIRANIB (AZD2171) IN ALVEOLAR SOFT PART SARCOMA

OBJECTIVES
Alveolar soft part sarcoma (ASPS) is a rare entity making up <1% of soft tissue sarcomas (STS). It is typically indolent but with a high incidence of metastatic disease, usually to lungs, but also unusual sites, such as brain. Response to conventional systemic treatment is poor. This is a preliminary report of the activity of cediranib in this disease.

METHODS
Efficacy and tolerability data were collected for 7 patients (pts) with ASPS; 1 treated in a randomized trial of two cediranib doses ± prophylactic antihypertensive therapy and 6 in a Phase II study in pts with imatinib refractory GIST or other STS. Cediranib was administered once daily PO at an initial dose of 45mg. Response was assessed using RECIST.


RESULTS
Median age at diagnosis was 30 years (range: 23-70). All pts had pulmonary metastases and 2 had additional sites of disease (brain, bone, intra-abdominal) at study entry.
Tolerability: Treatment was well tolerated; the most common side effects being fatigue, hoarse voice, hypertension, diarrhoea and sore mouth - generally grade 1-2 and manageable. 1 patient died following surgery for brain metastases.
Objective responses: 5 pts had a confirmed partial response and 2 pts stable disease.
6 patients remain on treatment with a median duration to date of 34 weeks (range15-97)

CONCLUSION
There is no effective systemic treatment for patients with advanced ASPS. These data demonstrate the exciting preliminary activity and safety of chronic administration of cediranib in this disease. Further investigation is warranted.

[Beth]

The PowerPoint presentation has been posted by the society. http://www.ctos.org/meeting/2008/presen ... ardner.ppt

[Olga]

Beth - can you and other people who read this and are interested in this development ask Pf.Judson if cediranib trial is going to be open for ASPS patients specifically worldwide? His e-mail is Ian.Judson@icr.ac.uk
as I understand he is a principal investigator with Astra Zeneca re.cediranib in sarcomas and probably the most influential person that might advance this drug to our trial.